Spero Therapeutics (NASDAQ:SPRO) Stock Rated Overweight in New Coverage at Cantor Fitzgerald

Equities researchers at Cantor Fitzgerald assumed coverage on shares of Spero Therapeutics (NASDAQ:SPRO) in a research report issued to clients and investors on Wednesday, Briefing.com reports. The firm set an “overweight” rating and a $6.00 price target on the stock. Cantor Fitzgerald‘s price objective would suggest a potential upside of 426.32% from the stock’s current price.

Several other research firms also recently weighed in on SPRO. Weiss Ratings downgraded Spero Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday. Compass Point raised shares of Spero Therapeutics to a “neutral” rating in a research report on Monday, September 14th. Zacks Research upgraded shares of Spero Therapeutics to a “hold” rating in a research note on Monday, September 14th. Finally, HC Wainwright upped their price target on Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Monday, September 14th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $6.00.

Spero Therapeutics Trading Up 6.5%

Shares of NASDAQ SPRO opened at $1.14 on Wednesday. Spero Therapeutics has a 12-month low of $1.04 and a 12-month high of $3.08. The business’s fifty day simple moving average is $1.18 and its 200-day simple moving average is $2.00.

Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.01. On average, research analysts forecast that Spero Therapeutics will post -0.58 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Spero Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Spero Therapeutics during the second quarter worth about $36,000. BlackRock Inc. purchased a new position in shares of Spero Therapeutics in the 2nd quarter worth $1,314,000. Alphabet Inc. acquired a new stake in Spero Therapeutics during the second quarter worth about $1,967,000. Global Retirement Partners LLC purchased a new position in shares of Spero Therapeutics in the 2nd quarter worth about $55,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Spero Therapeutics in the 2nd quarter valued at about $632,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens.

Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.